With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

The firm highlighted Eli Lilly's metabolic portfolio developments, noting that the pharmaceutical company quickly provided new information to investors shortly after releasing its ACHIEVE-1 data.

Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.

A high-level overview of Eli Lilly and Company (LLY) stock. View (LLY) real-time stock price, chart, news, analysis, analyst reviews and more.

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Check out our LLY stock chart to see a history of performance, ... Eli Lilly and Co. Eli Lilly and Co LLY. Stock XNYS Rating as of Jun 24, 2025. Read Company Report Download PDF.

Review Eli Lilly and Co (LLY:XNYS) stock and the current sustainability and ESG risk rating to help with your investing decisions.